Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2020 · 10-Q
Revenue$78.06M$78.06M+4.0% vs Q2 2019 Net Income$8.06M$8.06MN/M vs Q2 2019 EPS Diluted$0.23$0.23N/M vs Q2 2019 Gross Profit$48,364,000+83.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$43,854,000+199.8% Free Cash Flowderived$43,028,000+212.9% Margins · derivedGross margin62.0%+26.8 pt vs Q2 2019
Operating margin21.2%+27.9 pt vs Q2 2019
Net margin10.3%+16.6 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end